Identifying relevant HLA-F ligands
鉴定相关的 HLA-F 配体
基本信息
- 批准号:10593460
- 负责人:
- 金额:$ 10.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Abstract/Summary
· Our underlying hypothesis is that, unlike human classical and other non-classical MHC class I proteins, HLA-
F ligand recognition is focused on glycans, either as components of oligosaccharides, proteo/peptidoglycans, or
glycoproteins/glycopeptides – representing a paradigm shift in current understanding. This hypothesis is based
on a rigorous reevaluation of recent, otherwise seminal crystallographic and mass-spec results (1).
· Echoing FOA PA-19-066, our long-term overall goal is “to characterize antigen processing and presentation
[…] of novel peptidic and non-peptidic ligands presented by [HLA-F], and to determine the contribution of these
unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-
associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated dis-
eases.” Our first steps towards accomplishing this goal in this R21 will be to: (a) identify physiologically-
relevant ligand/s for HLA-F using rigorous biochemical approaches, focusing on glycopeptides and glycoconju-
gates; and (b) determine conditions for growing diffraction-quality co-crystals to support future crystallographic
structure determinations. These results will comprise the necessary preliminary results to support follow-on grant
applications to structurally, biologically, and functionally validate candidate HLA-F glycoligands.
· We will achieve these goals, and rigorously test our hypothesis, through the following Specific Aim: we will
use our novel ARTEMIS mass-spec peptide discovery platform, glycan arrays, and fragment screening ap-
proaches, to fully parse HLA-F ligand specificity for glycosylated ligands. Candidate ligands will be used to screen
crystallization conditions to support follow-on crystallographic studies to eventually structurally characterize
recognition mechanisms to fully parse specificity. Rigor will ultimately be achieved through careful biochemical
and structural validation, and the likelihood of success will be maximized by incorporating multiple, parallel ap-
proaches and experimental methods into the proposed scope to overcome potential confounders and pitfalls.
· Significance (from PA-19-066): “The classic understanding of antigen processing and presentation begins
with a protein fragment (peptide) associating with MHC molecules. […] These long-accepted paradigms regard-
ing antigen processing and presentation and T cell recognition are incomplete. Approximately 10% of antigenic
peptides can be derived from unconventional sources […]. Additionally, the antigen components that trigger non-
classical MHC I restricted CD8 T cells and unconventional or innate T cells include lipids and small-molecule
metabolites but are not well characterized. […] The objective of this research program is to promote the discovery
of unique antigenic ligands (peptidic and non-peptidic) and understand the immune responses to these ligands:
peptidic and non-peptidic ligands presented by non-classical MHC molecules: [HLA-F].”
项目摘要/总结
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Large libraries of single-chain trimer peptide-MHCs enable antigen-specific CD8+ T cell discovery and analysis.
- DOI:10.1038/s42003-023-04899-8
- 发表时间:2023-05-16
- 期刊:
- 影响因子:5.9
- 作者:Chour, William;Choi, Jongchan;Xie, Jingyi;Chaffee, Mary E. E.;Schmitt, Thomas M. M.;Finton, Kathryn;DeLucia, Diana C. C.;Xu, Alexander M. M.;Su, Yapeng;Chen, Daniel G. G.;Zhang, Rongyu;Yuan, Dan;Hong, Sunga;Ng, Alphonsus H. C.;Butler, Jonah Z. Z.;Edmark, Rick A. A.;Jones, Lesley C. C.;Murray, Kim M. K. M.;Peng, Songming;Li, Guideng;Strong, Roland K. K.;Lee, John K. K.;Goldman, Jason D. D.;Greenberg, Philip D. D.;Heath, James R. R.
- 通讯作者:Heath, James R. R.
Large libraries of single-chain trimer peptide-MHCs enable rapid antigen-specific CD8+ T cell discovery and analysis.
大型单链三聚体肽 MHC 文库能够快速发现和分析抗原特异性 CD8 T 细胞。
- DOI:10.21203/rs.3.rs-1090664/v1
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Heath,James;Chour,William;Choi,Jongchan;Xie,Jingyi;Chaffee,Mary;Schmitt,Thomas;Finton,Kathryn;Delucia,Diana;Xu,Alexander;Su,Yapeng;Chen,Daniel;Zhang,Rongyu;Yuan,Dan;Hong,Sunga;Ng,Alphonsus;Butler,Jonah;Edmark,Rick;Jones,
- 通讯作者:Jones,
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Roland K Strong其他文献
Roland K Strong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Roland K Strong', 18)}}的其他基金
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 10.45万 - 项目类别:
TCR-like antibodies for HPV-induced cancer basic research and theranostics
用于 HPV 诱导的癌症基础研究和治疗诊断的 TCR 样抗体
- 批准号:
9319153 - 财政年份:2016
- 资助金额:
$ 10.45万 - 项目类别:
TCR-like antibodies for HPV-induced cancer basic research and theranostics
用于 HPV 诱导的癌症基础研究和治疗诊断的 TCR 样抗体
- 批准号:
9178025 - 财政年份:2016
- 资助金额:
$ 10.45万 - 项目类别:
Structure/function studies of immunogen recognition by anti-HIV antibody b12
抗HIV抗体b12免疫原识别的结构/功能研究
- 批准号:
8463117 - 财政年份:2013
- 资助金额:
$ 10.45万 - 项目类别:
B7-based, CD28 or CTLA-4-specific agonists and antagonists for tolerance inductio
基于 B7 的 CD28 或 CTLA-4 特异性激动剂和拮抗剂,用于耐受诱导
- 批准号:
8302052 - 财政年份:2012
- 资助金额:
$ 10.45万 - 项目类别:
B7-based, CD28 or CTLA-4-specific agonists and antagonists for tolerance inductio
基于 B7 的 CD28 或 CTLA-4 特异性激动剂和拮抗剂,用于耐受诱导
- 批准号:
8432007 - 财政年份:2012
- 资助金额:
$ 10.45万 - 项目类别:
Structure/function studies of immunogen recognition by anti-HIV antibody b12
抗HIV抗体b12免疫原识别的结构/功能研究
- 批准号:
8117982 - 财政年份:2011
- 资助金额:
$ 10.45万 - 项目类别:
Microbial siderophore-specific innate immune responses
微生物铁载体特异性先天免疫反应
- 批准号:
7022967 - 财政年份:2005
- 资助金额:
$ 10.45万 - 项目类别:
Microbial siderophore-specific innate immune responses
微生物铁载体特异性先天免疫反应
- 批准号:
6872755 - 财政年份:2005
- 资助金额:
$ 10.45万 - 项目类别:
相似海外基金
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
- 批准号:
10721983 - 财政年份:2023
- 资助金额:
$ 10.45万 - 项目类别:
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
NSCLC 中的 HLA B44 基序新表位:评估它们对 TME 的影响,并将它们添加到模型中已建立的标记中,以预测有或没有化疗的 PD-1 抑制的持久益处
- 批准号:
10681851 - 财政年份:2023
- 资助金额:
$ 10.45万 - 项目类别:
The novel role of HLA-E restricted CD8 regulatory T cells in kidney allograft rejection
HLA-E限制性CD8调节性T细胞在肾同种异体移植排斥中的新作用
- 批准号:
10564689 - 财政年份:2023
- 资助金额:
$ 10.45万 - 项目类别:
Immune evasion by SARS-CoV-2: the role of HLA class I
SARS-CoV-2 的免疫逃避:HLA I 类的作用
- 批准号:
10575292 - 财政年份:2022
- 资助金额:
$ 10.45万 - 项目类别:
HLA Immunogenetics and kidney allograft outcomes
HLA 免疫遗传学和肾同种异体移植结果
- 批准号:
10566338 - 财政年份:2022
- 资助金额:
$ 10.45万 - 项目类别:
HLA Fine Mapping to Elucidate S. aureus Susceptibility
HLA 精细作图阐明金黄色葡萄球菌敏感性
- 批准号:
10490895 - 财政年份:2021
- 资助金额:
$ 10.45万 - 项目类别:
HLA Fine Mapping to Elucidate S. aureus Susceptibility
HLA 精细作图阐明金黄色葡萄球菌敏感性
- 批准号:
10344003 - 财政年份:2021
- 资助金额:
$ 10.45万 - 项目类别:
Development of Conformer-Specific Anti-HLA Class II mAbs
构建体特异性抗 HLA II 类单克隆抗体的开发
- 批准号:
10330612 - 财政年份:2021
- 资助金额:
$ 10.45万 - 项目类别:
Advancing HLA-"Humanized" Models for T1D Therapy Development
推进 T1D 治疗开发的 HLA“人性化”模型
- 批准号:
9256822 - 财政年份:2016
- 资助金额:
$ 10.45万 - 项目类别: